29PD - Downregulation of FBP1 promotes tumor metastasis and indicates poor prognosis in gastric cancer via regulating epithelial-mesenchymal transition

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Basic science and translational research
Topics Gastric Cancer
Translational Research
Presenter Jing Li
Citation Annals of Oncology (2016) 27 (suppl_9): ix9-ix18. 10.1093/annonc/mdw574
Authors J. Li, J. Tong
  • Department Of Oncology, Yangzhou NO.1 People’s Hospital, The Second Clinical School of Yangzhou University, 225009 - Yangzhou/CN



Recent studies indicated that some glycolytic enzymes are complicated, multifaceted proteins rather than simple components of the glycolytic pathway. FBP1 plays a vital role in glucose metabolism, but its role in gastric cancer tumorigenesis and metastasis has not been fully understood.


The prognostic value of FBP1 was first studied in The Cancer Genome Atlas (TCGA) database and validated in an in-house database. The effect of FBP1 on cell proliferation and metastasis was examined in vitro. Nonparametric test and Log-rank test were used to evaluate the clinical significance of FBP1 expression.


In the TCGA cohort, FBP1 mRNA level were shown to be predictive of overall survival in gastric cancer (P = 0.029). In the validation cohort, FBP1 expression wasinversely correlated with advanced N stage (P = 0.021) and lymphovascular invasion (P = 0.011). Survival analysis demonstrated that FBP1 was an independent predictor for both overall survival (P = 0.004) and disease free survival (P 


In conclusion, downregulation of FBP1 promotes gastric cancer metastasis by facilitating EMT and acts as a potential prognostic factor and therapeutic target in gastric cancer.

Clinical trial indentification

Legal entity responsible for the study

JIng Li




All authors have declared no conflicts of interest.